Barinthus Biotherapeutics (BRNS) Projected to Post Earnings on Friday

Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Barinthus Biotherapeutics to post earnings of ($0.27) per share and revenue of $0.22 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 12:30 PM ET.

Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. On average, analysts expect Barinthus Biotherapeutics to post ($0.93) EPS for the current fiscal year and ($1.07) EPS for the next fiscal year.

Barinthus Biotherapeutics Stock Performance

NASDAQ BRNS opened at $0.74 on Friday. The company has a fifty day simple moving average of $0.73 and a 200 day simple moving average of $0.66. The company has a market cap of $30.23 million, a P/E ratio of -0.72 and a beta of -0.37. Barinthus Biotherapeutics has a 1 year low of $0.51 and a 1 year high of $1.83.

Analyst Ratings Changes

Several research analysts recently commented on BRNS shares. Zacks Research upgraded shares of Barinthus Biotherapeutics to a “hold” rating in a report on Wednesday, August 26th. Weiss Ratings cut shares of Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $4.00.

Read Our Latest Research Report on Barinthus Biotherapeutics

Barinthus Biotherapeutics Company Profile

(Get Free Report)

Barinthus Biotherapeutics plc is a clinical-stage biotechnology company developing T-cell immunotherapies designed to treat autoimmune diseases, chronic infections and cancer. The company’s approach is intended to direct or regulate immune responses with greater specificity, with the goal of restoring immune tolerance or strengthening disease-fighting T-cell activity.

Barinthus’ product pipeline includes VTP-1000, an investigational antigen-specific therapy being developed for celiac disease, and VTP-300, a therapeutic vaccine candidate aimed at chronic hepatitis B infection.

Featured Stories

Earnings History for Barinthus Biotherapeutics (NASDAQ:BRNS)

Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.